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ABSTRACT
Bone engineering of localized craniofacial osseous defects or deficiencies by stem cell therapy offers strong prospects to improve
treatment predictability for patient care. The aim of this phase 1/2 randomized, controlled clinical trial was to evaluate reconstruction
of bone deficiencies of the maxillary sinus with transplantation of autologous cells enriched with CD90þ stem cells and CD14þ
monocytes. Thirty human participants requiring bone augmentation of the maxillary sinus were enrolled. Patients presenting with
50% to 80% bone deficiencies of the maxillary sinus were randomized to receive either stem cells delivered onto a b-tricalcium
phosphate scaffold or scaffold alone. Four months after treatment, clinical, radiographic, and histologic analyses were performed
to evaluate de novo engineered bone. At the time of alveolar bone core harvest, oral implants were installed in the engineered
bone and later functionally restored with dental tooth prostheses. Radiographic analyses showed no difference in the total bone
volume gained between treatment groups; however, density of the engineered bone was higher in patients receiving stem cells.
Bone core biopsies showed that stem cell therapy provided the greatest benefit in themost severe deficiencies, yielding better bone
quality than control patients, as evidenced by higher bone volume fraction (BVF; 0.5 versus 0.4; p¼ 0.04). Assessment of the relation
between degree of CD90þ stem cell enrichment and BVF showed that the higher the CD90 composition of transplanted cells, the
greater the BVF of regenerated bone (r¼ 0.56; p¼ 0.05). Oral implants were placed and restored with functionally loaded dental
restorations in all patients and no treatment-related adverse events were reported at the 1-year follow-up. These results provide
evidence that cell-based therapy using enriched CD90þ stem cell populations is safe for maxillary sinus floor reconstruction and
offers potential to accelerate and enhance tissue engineered bone quality in other craniofacial bone defects and deficiencies
(Clinicaltrials.gov NCT00980278). © 2015 American Society for Bone and Mineral Research.
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Introduction
Oral and craniofacial bone defects secondary to congenitaldeformities, disease, and injury are very common and
highly variable, representing a significant health care burden.(1)
When these conditions are also associated with tooth loss or the
congenital absence of teeth, alveolar bone of the jaw does not
receive the functional stimulus innately produced by the teeth
and their supporting structures and, as a result, further bone
resorption results.(2) The consequences of these processes are
severe horizontal and vertical bone deficiencies and inadequate
bone volume to restore these areas of the jaw with functional
and esthetic tooth replacements. In such cases, major alveolar
bone reconstruction followed by dental prosthetic rehabilitation
to reestablish form, function, and esthetics to these regions of
the oral cavity are needed.(3)
When appropriate conditions are present, oral implant
therapy serves as the most functional, esthetic, predictable,
and therapeutic treatment option for the replacement of
missing teeth.(4) However, a key determinant underlying the
success of oral implant therapy is the qualitative and quantita-
tive nature of the bone support into which implants are
placed.(5) It has been long known that among those patients
who seek oral implant therapy, a significant number lack
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sufficient bone and require bone grafting procedures to enable
implant placement and to improve function, predictability, and
longevity of oral implants.(6)
Regardless of the extent or severity of the bone defects, the
success of bone regenerative and reconstructive procedures
used to correct them depends on the presence of osteogenic
and vascular precursor cells resident in the surrounding
tissues.(7) During the healing phase of regenerative therapies,
some of these cells enter the defect and differentiate into
osteoblasts that produce bone matrix and a vasculature that
sustains architecture.(8) The dependence of these wound-
healing and regenerative processes makes small, localized
defects more manageable and predictable to treat, whereas
larger reconstructions of severe deficiencies are much more
challenging. Despite recent advances in tissue engineering and
regenerative medicine, reconstruction of large defects still relies
primarily on treatments involving large autogenous grafts,
allografts, xenografts, and synthetic alloplastic materials.(9)
Newer, more targeted cell and tissue-based therapies are
needed to overcome the problematic limitations of traditional
treatments.(10,11)
Stem cell therapy is a promising tissue engineering strategy to
enhance tissue regeneration and promote de novo formation of
both hard and soft tissues.(12–14) Recently, clinical reports have
emerged that investigate cell therapy for craniofacial applica-
tions.(8,15–24) These early reports have had modest and mixed
results, but a major limitation common to them is the limited
characterization of the cell populations used for therapy.
Insufficient knowledge regarding the cell population used as
part of a stem cell therapy makes it difficult to understand the
mechanisms underlying the study outcomes. The aims of this
randomized, controlled, phase 1/2 clinical trial were to determine
if autologous bone marrow–derived cells, including expanded
CD90þ mesenchymal stem cells and CD14þ monocytes and
macrophages, would be safe and efficacious in the treatment of
large bone deficiencies of the edentulous maxilla. Bone
deficiencies in these edentulous areas preclude restoration of
the areas with oral implants and teeth because of the close
proximity of the maxillary sinus. Surgical procedures involving
augmentation of the sinus are routinely used to regenerate bone
in these areas for oral implant installation, and many of these
procedures involve the use of bone grafts.(25,26) As such,
evaluation of regenerated and engineered bone in these
maxillofacial sites enables better understanding of factors
underlying successful treatment outcomes associated with cell
therapy. The stem cell therapy employed in this study was
comparedwith a control treatment using an alloplast device only.
Materials and Methods
Study design, patient selection, and randomization
Under an Investigational New Drug Application (US Food and
Drug Administration IND# 13662), the FDA approved the
treatment of up to 30 patients with the proposed stem cell
therapy (Clinicaltrials.gov# NCT00980278). After US Food and
Drug Administration and University of Michigan Institutional
Review Board (IRB) approval, 30 patients with severe bone
atrophy of the upper jaw and in need of bone reconstruction for
oral implant and dental reconstruction were recruited to
participate in this phase 1/2 randomized, controlled clinical
trial. This sample size was chosen for feasibility rather than
statistical precision. Through a computer-generated
randomization schedule, half(15) of the patients were random-
ized to receive the stem cell therapy (ixymyelocel-tþbeta-
tricalcium phosphate [b-TCP] scaffold; Cerasorb, Curasan AG,
Germany) and the other half randomized to receive the control
treatment (b-TCP scaffold alone), with each subject only
receiving one of the two possible treatments. Of the 30 enrolled,
4 withdrew from the study before undergoing any treatment-
related procedures. Of the 26 participants, 2 dropped out before
study completion (Fig. 1A). The primary outcome variables were
bone volume fraction (BVF) and bone mineral density (BMD),
and these were measured by histological and micro-computed
tomography (mCT) analyses at 4 months post-treatment.
Secondary outcome variables included: increase in linear
radiographic bone height, increase in sinus bone volume,
bone volume/initial graft volume ratio, soft tissue wound
healing, postoperative pain score, clinical bone density on
reentry of the grafted site, and quality-of-life assessment of
treatment. Post hoc analyses included % CD90þ cells delivered
relative to BVF and BMD.
Ixymyelocel-t production
In the study participants who were designated to be in the stem
cell therapy group, 12 to 14 days before initial surgical
treatment, 50 to 70 cc of bone marrow were aspirated from
the posterior iliac crest. The cell processing for generation of the
autologous cell product, ixmyelocel-t (Aastrom Biosciences Inc.,
Ann Arbor, MI, USA), has been previously described.(27) Briefly,
the collected marrow was transferred to a sterile blood bag and
bone marrow mononuclear cells (BMMNC) were purified by
Ficoll density gradient centrifugation. BMMNC were then
inoculated into a bioreactor, which is a proprietary computer-
controlled, automated cell-processing unit, the Aastrom Repli-
cell System (Aastrom Biosciences). This system incorporates
single-pass perfusion in which fresh medium flows slowly over
cells without retention of waste metabolites or differentiating
cytokines. The culture medium consists of Iscove’s modified
Dulbecco’s medium (IMDM), 10% fetal bovine serum, 10% horse
serum, and 5mM hydrocortisone. After cultivation for 12 days at
37 °C, 5% CO2, with a ramped continuous medium perfusion
schedule, the ixymyelocel-t product was harvested by trypsini-
zation, washed in a physiologic buffer, and collected into a
sterile bag, where it was stored until the time of transplantation.
The final cell composition was composed of a mixture of bone
marrow–derived cells, including different concentrations of
expanded CD90þmesenchymal stem cells, CD14þmonocytes/
macrophages, and mononuclear cells from the original bone
marrow aspirate.
Flow cytometric characterization of cell populations
All cell populations used in the stem cell therapies were
characterized with respect to %CD90þ cells, %CD14þ cells, cell
concentration of the final cell suspension, and number of cells
delivered. In the flow cytometry analyses, all events were initially
gated on light scatter (Forward Scatter versus Side Scatter) and
then assessed for membrane integrity via 7AAD staining (ie,
estimation of viability). Using the nucleic acid probe 7AAD,
membrane-compromised events were excluded from further
analysis. All subsequent plots were gated on scatter and 7AAD
exclusion for phenotypic analysis. Thus, CD14þ and CD90þ
measurementswere based on gates for light scatter assessment/
debris exclusion and “viability” (7AAD negative). As the original
cell inoculum was cultured and the cells were expanded, there
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was an increase in autofluorescence, which is displayed by the
CD90þ and CD14þ Auto positive (CD14þAutoþ) populations.
The CD14þ populations typically display varying levels of
autofluorescence, which were separated by gates to distinguish
the CD14þ autofluorescent-positive (CD14þAutoþ) and
CD14þ autofluorescent-negative (CD14þAuto-) populations.
Clinical procedures
Twelve to 14 days after the bone marrow aspiration, sinus
elevation procedures were performed with simultaneous bone
grafting according to the technique described by Tatum(28)
(Supplemental Video S1). {Video S1} Briefly, a full-thickness
mucoperiosteal crestal incision and flap was made with vertical
extensions and the lateral aspect of the maxilla was exposed. A
window osteotomy was then prepared on the lateral aspect of
themaxilla to access themaxillary sinus cavity. The Schneiderian
membrane of the sinus was then gently reflected from the floor
of the sinus cavity and elevated 1 to 2 cm from its original height.
The sinus cavity was then grafted under the elevatedmembrane
by placing either the alloplast bone voidmaterial b-TCP alone or
the b-TCP loaded with the cells. After placement of the graft,
the sinus access window opening was then covered with a
bioresorbable, occlusive collagen membrane, and the flap was
sutured to attain primary closure. The bone graft material for
these procedures serves to stimulate bone regeneration in the
floor of the sinus cavity, resulting in vertical augmentation of
the deficient bone height to enable future dental implant
placement.
Bone height deficiencies ranged from 40% to 80%. Severe
bone defects were classified as those where bone height
deficiencies of >50% were present (ie, where the initial bone
height was <50% of that required for oral implant placement
with functional dental restoration). In the stem cell therapy
group, the volume of cell suspensions delivered to each patient
was determined by the volume of b-TCP used, and these
Fig. 1. Trial profile. (A) Consort diagram of patient distribution. (B) Study timeline.
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volumes were mixed at a 1:1 ratio 30minutes before delivery.
The final volume of b-TCP used in both control and stem cell
therapy groups was determined by the extent of the bone
height deficiency. The amount of scaffold placed at the time of
grafting was recorded for each patient and correlated to the
regenerated bone volume fraction (BVF¼ the proportion of
regenerated bone composed of mineralized bone tissue) of the
bone core biopsy. This measure was reported as “initial graft
volume versus BVF.” Additionally, the percentage of CD90þ cells
within each of the patient cell populations was recorded and
correlated with the regenerated BVF, and this measure reported
as “% CD90þ cells versus BVF.”
Clinical assessments, bone biopsy harvest, and oral
implant installation
At 1, 2, and 4 weeks after surgery, the grafted sites were
inspected and soft-tissue healing was evaluated with a wound-
healing index (WHI) according to the following scheme:(29)
0¼mature wound healing; 1¼ erythema; 2¼bleeding;
3¼ flap mobility; 4¼ suppuration; 5¼ necrosis. Reentry pro-
cedures of the grafted sites were performed 4 months after
sinus floor augmentation. Bone biopsy cores of approximately
2 10mm in dimension were removed with a trephine drill
(Ace Surgical Supply Co., Inc., Brockton, MA, USA) from areas
corresponding to where the implants were going to be placed
and the region(s) of the previous sinus graft. Upon drilling into
the bone, clinical bone density was recorded according to
tactile sensation as a measure of bone density. The bone
biopsy cores were immediately fixed in 10% neutral-buffered
formalin to enable histomorphometric and mCT analyses. Bone
biopsies were scanned for mCT analyses and processed for
histological analyses in the University of Michigan’s School of
Dentistry Histology Core. Oral implants (Straumann, Straumann
AG, Basel, Switzerland) of 10 to 12mm in length were placed in
the grafted sites. Sinus augmentation procedures, and implant
installations were performed by two different surgeons; bone
core biopsy procedures were performed by one surgeon.
3D cone beam computed tomographic (CBCT) analysis
CBCT data model construction, registration, and visualization for
volumetric assessment of the augmentation procedures was
performed as previously described, withminor modifications.(30)
Grayscale isotropic models were constructed from the CBCT
images with a voxel dimension of 0.4 0.4 0.4mm. Three-
dimensional surface models of the maxillary sinuses at baseline
and post-treatment were constructed for each patient using ITK-
SNAP (open-source software; http://www.itksnap.org). Baseline
and post-treatment 3D models were registered according to
anatomical landmarks, specifically the anterior nasal spine and
the nasal crest of the maxillary bone within the floor of the nasal
cavity. These regions were chosen because of the relative
stability in the structure over a span of a few months. An
automated, voxel-based registration method was performed
with 3D Slicer (open-source software; http://www.slicer.org).
Visualization and assessment of the regenerated bone were
performed using CMF application software (developed at the
M. E. Muller Institute for Surgical Technology and Biomechanics,
University of Bern, Bern, Switzerland, under the funding of the
Co-Me network; http://co-me.ch). Segmentation of the baseline
and follow-up scans were performed using the ITK-SNAP
software to detect the differences between the superimposed
3D images and to quantify the newly regenerated bone volume.
The ratio of newly formed bone to amount of b-TCP used in the
grafting procedure will be quantified and compared.
mCT analysis of bone biopsy cores
Nondecalcified bone cores were scanned and the data
quantified using a 3D mCT 100 cabinet cone-beam mCT system
(Scanco USA, Inc., Wayne, PA, USA). The specimens were fitted in
a cylindrical sample holder, with the longitudinal axis of the
bone core oriented in a horizontal position, and scanned at a
resolution of 12 12 12mm. 3D isosurface images for the
analysis of sample scans were constructed using the GEMS
MicroView software (GE Healthcare, Little Chalfont, UK). Analysis
was performed by a calibrated masked examiner as previously
described with minor modifications.(31) The mean threshold
grayscale values for bone and residual scaffold material (b-TCP)
were used to calculate the BMD and the fractional bone volume
(BV/TV) of newly formed mineralized bone at the graft site. The
grafted site was demarcated visually as the region located
superior (apical) to the dense, mature lamellar bone.
Bone histomorphometry
After scanning for mCT imaging, bone cores were processed for
histological analysis. Histomorphometric analysis of decalcified,
hematoxylin and eosin (H&E)-stained sections were performed
to determine bone formation. Using an E-800 light microscope,
histologic sections from each sample at each time point were
scanned and imported into Adobe Photoshop (Adobe Systems,
Inc., Mountain View, CA, USA). Identification of bone was based
on morphology of stained tissue and the identification of cells
lining (osteoblasts) and within (osteocytes) this tissue. Bone
tissue area for each section was determined by dividing the total
number of bone pixels by the total number of pixels in the tissue
section based on color using Image Pro Plus Software.
Statistical analyses
Safety analyses were performed at each post-baseline visit and
included reporting of adverse events by body system and by
severity and relationship to the cell therapy, as assessed by the
investigator. Statistical analysis was performed with the
statistical software package R (R Foundation for Statistical
Computing, Vienna, Austria). Plots represent means standard
errors; differences in means between the two treatment groups
were assessed with a two-sample t test. Correlation was based
upon Pearson’s product-moment correlation coefficient (r),
with significance based on Fisher’s Z-transformation. Statistical
significance was defined as p < 0.05.
This trial is registered with ClinicalTrials.gov, number
NCT00980278.
Results
Study design and patients
Throughout the course of the study, there were no serious,
study-related adverse events that were reported in examination
of comprehensive safety assessments during the trial (Supple-
mental Table S1). {TBL S1} Fig. 1A displays the Consort Diagram
of the patient allocation to groups. After determination of study
eligibility and enrollment, 4 patients elected not to pursue
treatment as part of the study and a total of 26 patients were
treated (n¼ 13 per group). The baseline demographic character-
istics of all study participants are shown in Table 1,{TBL 1} and
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there were no differences between the two treatment groups
with regard to these parameters. Fig. 1B shows the trial
sequence of events and timeline.
Complete surgical and prosthetic reconstruction of
individual and multiple sites
When posterior teeth of the maxilla are removed, because of
their proximity to the sinus cavities, the sinuses enlarge
(pneumatize) and disuse atrophy of the bone in these regions
poses significant constraints on the ability to place oral implants
because of insufficient bone height, volume, and quality. For
stable placement and restoration of oral implants in the
posterior maxilla in these cases, it is desirable to have a
minimum of 10mm of bone height between the alveolar crest
and the maxillary sinus cavity.(32,33) All patients treated in this
study were in need of bone-regenerative procedures for oral
implant placement because of bone height deficiencies ranging
from 50% to 80%. Additionally, all patients treated were in need
of either localized site bone reconstruction (for replacement of
one tooth) or multiple site bone reconstruction (for replacement
of up to four teeth) in this area. The clinical sequence of
treatment procedures for reconstruction of localized bone
deficiencies for single-tooth replacements in the control and
stem cell therapy groups involved grafting with the b-TCP
scaffold or the stem cells on the scaffold as part of a routine sinus
lift procedure. The clinical procedures were no different
between treatment groups, and in both groups, favorable
function and esthetics were achieved with the final tooth
restorations (Supplemental Fig. S1). The clinical sequence of
treatment procedures for reconstruction of larger regions of
bone deficiencies for areas requiring the replacement of
multiple teeth was slightly variable, depending on the number
of sites treated and respective number of teeth being replaced
(between two and four) (Fig. 2).
The clinical surgical parameters of the two treatments were
equivalent between groups (Supplemental Table S2). There was
one graft failure in the treatment group and one implant failure
in the control group. In addition to the clinical surgical treatment
parameters documented, the soft-tissue wound healing after
grafting was evaluated. One, two, and four weeks postopera-
tively after initial regenerative treatment, there was no
difference in the soft-tissue profiles of healing between
treatment groups, nor was there a difference in postoperative
discomfort between groups (Supplemental Fig. S2).
Because of the high morbidity and postoperative discomfort
associated with large oral and craniofacial reconstructive
procedures, one final clinical assessment at the conclusion of
treatment involved a survey of patient psychosocial factors
associated with the stem cell therapy treatment. In this survey of
patient quality-of-life variables (Supplemental Fig. S3), despite
undergoing the bone marrow aspiration procedure for isolation
of the autologous cells, patients in the stem cell therapy group
were equally satisfied with their treatment compared with those
undergoing standard of care procedures, and all indicated they
would have these procedures performed again if needed. One of
the patients in the cell therapy group indicated that themarrow-
harvesting procedures resulted in significant discomfort, yet this
individual also indicated that he/she would have the procedure
performed again if needed. One patient in the control group
indicated that he/she would not have the procedure performed
again if ever necessary.
Linear radiographic bone height changes
Radiographic bone height is a key clinical determinant to assess
the need for bone grafting in the areas of the posterior maxilla in
proximity to the maxillary sinuses. Hence, linear radiographic
changes in bone height before and after bone graft reconstruc-
tion were evaluated. Significant changes in bone height were
achieved in the control and stem cell therapy groups (Fig. 3A–D,
G–J; Table 2). {FIG3}{TBL 2} Alveolar bone height of the posterior
maxilla beneath themaxillary sinus increased two- and threefold
in most cases and up to fivefold in two of the cases in the stem
cell therapy group. Overall, there was no difference in the mean
linear radiographic bone height changes between the treatment
groups (Table 2). After oral implant placement and 6 months of
functional loading of implants with dental restorations, the bone
consolidation around the implants remained stable radiograph-
ically in both groups for all patients (Fig. 3E, F, K, L).
Correlation of CD90þ cells with BVF
CD90þmesencyhmal stem cells have been previously shown to
have strong regenerative and bone differentiation potential. The
stem cell therapy described utilized autologous cell populations,
which, relative to the initial bone marrow aspirate, are enriched
100-fold for CD90þ cells and CD14þ cells during the cell
expansion process (Fig. 4A). Between patients receiving the stem
cell therapy, there was heterogeneity in the final percentage of
enriched CD90þ cells ranging from 15% to 40% (Supplemental
Table S3). b-TCP particles were used as a cell scaffold to deliver
the cells into the bone defect, and 4 months after delivery of the
cells or the scaffold alone, bone biopsies from the regenerated
tissue were retrieved and evaluated with 3D mCT. Intact bone
Table 1. Patient Demographic Data
Control Stem cell therapy
No. of patients enrolled (no. of patients treated surgically) 15 (13) 15 (13)
Females 10 10
Mean age, years (range) 49.1 (26–65) 53 (27–66)
Ethnicity
White 14 12
African American 1 1
Asian 0 2
Right maxilla/left maxilla 8/7 8/7
No. of patient withdrawals of consent before study entry 2 2
Mean baseline alveolar bone height (range) 5.0 (2.5–6.2) 3.5 (2.1–6.1)
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cores could not be harvested from 3 patients because of
technical challenges in the retrieval of these specimens, yet
these analyses enabled the determination of the extent to which
regenerated tissue was composed of residual b-TCP graft
particles and regenerated bone tissue (Fig. 4B). In evaluating all
the bone cores retrieved, there was a significant negative
correlation (r¼–0.75, p¼ 0.02) between the amount of graft
placed and the proportion of bone formed (BVF) within the
regenerated tissue (Fig. 4C). Thus, depending on the size of the
defect, as the amount of scaffold material increased, the quality
of the regenerated bone tissue decreased (as measured by BVF).
However, it was striking to note that in the stem cell therapy
group, the percentage of CD90þ cells in different cell
populations yielded an enhancement in the regenerated bone
quality, with it being a significant positive correlation between
percent CD90þ cells and BVF (r¼ 0.56; p¼ 0.05) (Fig. 4C). This
relationship was consistent with the clinical evaluation of the
regenerated bone density, where the clinical bone density was
highest in the patients treated with the stem cell therapy
(Supplemental Fig. S4).
3D volumetric changes in bone formation
CBCT was used to evaluate 3D changes in the bone volume
within the treated areas of the sinus cavity. Overall, there was a
significant increase in bone volume in both treatment groups,
but no difference between groups in the ratio of regenerated
bone volume to initial grafted volume was observed (Fig. 5A, B;
Table 2). Using mCT and histological analyses to evaluate the
qualitative nature of the de novo bone, it appeared that the BVF
of the regenerated bone was higher in biopsies retrieved from
patients who received the stem cell therapy. Quantitatively, the
BVF for biopsies from the stem cell therapy group (0.49) was
higher than that for the control group (0.43) (Table 2).
Additionally, the bone quality of regenerated bone was
significantly enhanced in patients receiving the stem cell
therapy in the most severe deficiencies (>50% deficiency in
bone height). In these cases, the regenerated bone biopsies
from patients receiving the stem cell therapy had a significantly
greater BVF than those cores harvested from the control group
(0.5 versus 0.4, respectively; p¼ 0.04) (Fig. 5C).
Fig. 2. Clinical treatment sequence for multiple site sinus bone graft reconstruction of severe bone atrophy. (A) Clinical images of the occlusal (top) view
of the initial edentulous region of patients treated in the (A) control or (I) stem cell therapy group. Buccal (lateral) views of the surgical site located above
the edentulous region in the (B) control and (J) stem cell therapy groups show preparation of a window osteotomy in the lateral aspect of the maxilla for
access to the Schneiderian membrane of the maxillary sinus cavity. After elevation of the maxillary sinus, the b-TCP (C) scaffold or stem cells (K) on the
scaffold are placed in the sinus cavity and, after closure of the surgical area, occlusal views of the edentulous areas 2 weeks after healing are shown (D, L).
Four months after control or stem cell treatment, oral implants (E, M) are placed in the edentulous areas of the grafted regions and allowed to integrate
into the bone for 6 months (F, N). At 6 months, implants in both treatment groups are biomechanically loaded with functional dental prosthetics,
restoring the edentulous areas with teeth, as shown in the occlusal (G, O) and buccal views (H, P).
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Discussion
The prospect that stem cell therapies offer significant advan-
tages over traditional approaches for oral and craniofacial
reconstruction has led to the development of an immense body
of work characterizing different stem cell populations and their
regenerative potential. Nonetheless, to date, there has been
limited translation of this work toward craniofacial applica-
tions.(21–25) In this report, we describe an autologous stem cell
therapy used to engineer bone tissue in moderate-severe bone
deficiencies of the maxilla in close proximity to the maxillary
sinuses. De novo bone regeneration was sufficient to stably
place oral implants, which were ultimately used to functionally
support dental prostheses. A key finding from this study was
that compared with the control group, better-quality bone was
formed in patients who received the stem cell therapy and bone
quality significantly correlated with the percentage of autolo-
gous CD90þ cells transplanted. Additionally, patients who
underwent the cell therapy indicated that they were completely
satisfied with the treatment outcome, did not have to
significantly alter daily life activities as a result of treatment,
and would have the same procedures performed again if
needed.
Autogenous, allogeneic, and alloplast bone “void fillers” are
typically grafted in the sinus cavity, and all modalities have been
shown to generate sufficient height and bone volume for stable
Fig. 3. Radiographic evaluation of sinus grafts and implant stability 6 months after functional loading. Cross-sectional images from CBCT scans showing
initial bone height in localized reconstructions (single site/tooth) of the (A) control and (B) stem cell therapy groups and bone height 4 months after
treatment (C, D) in both groups. (E, F) Periapical radiographs show bone consolidation around the implants 6 months after functional restoration of the
restored areas with a tooth. Cross-sectional images from CBCT scans showing initial bone height in multiple site reconstructions (2 to 4 teeth) of the
control (G) and stem cell therapy (H) groups and bone height 4 months after treatment (I, J) in both groups. (K, L) Periapical radiographs show bone
consolidation around the implants 6 months after functional restoration of the restored areas with teeth.
Table 2. Cone Beam and mCT 1° and 2° Outcome Measures
Outcome variables Control Stem cell therapy
Increase in linear radiographic bone height (mean, mm SD) 12.8 (2.8) 12.2 (3.3)
Increase in sinus bone volume (mean, cm3 SD) 2.1 (0.9) 1.8 (1.0)
Final bone volume/initial graft volume ratio (mean, SD) 0.64 (0.2) 0.51 (0.3)
Bone volume fraction of bone core (mCT) (mean, SD) 0.43 (8.1) 0.49 (7.2)
Bone mineral density of bone core (mCT) (mean, mg/mm3 SD) 0.79 (0.05) 0.78 (0.02)
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Fig. 4. Cell populations with higher percentages of CD90þ cells yield better quality of regenerated bone. (A) Representative flow cytometric analysis
from a patient shows enrichment of CD90þ and CD14þ cell populations from the initial aspirate to the final cell population used for treatment. All events
are initially gated on light scatter (FS versus SS) and then assessed for membrane integrity via 7AAD staining (ie, estimation of viability). An increase in
autofluorescence throughout the cell expansion process can be found in the Control, CD90þ , and CD14þAutoþ /CD14þAuto- plots. The CD14þ
populations display varying levels of autofluorescence, which are separated by gates to distinguish the CD14þ autofluorescent-positive (CD14þAutoþ)
and CD14þ autofluorescent-negative (CD14þAuto-) populations. (B) mCT images of representative bone biopsies from the control (scaffold only) and
stem cell therapy groups clearly show residual grafted scaffold (b-TCP) particles in the grafted zone 4 months after grafting. The zone of regenerated
bone is delineated from the native bone (yellow hashed line) and in the stem cell group is composed of more bone relative to residual graft compared
with the control group. (C) For all patients between both the control and stem cell therapy groups, there was a significant inverse relationship between
the amount of scaffold placed at the time of grafting and the bone volume fraction (the proportion of regenerated bone composed of mineralized bone
tissue) of the bone biopsy (Initial graft volume vs. BVF). For only those patients receiving the stem cell therapy, there was a significant positive correlation
between the percentage of the CD90þ cells (within the cell populations delivered) and the BVF (% CD90þ cells vs. BVF).
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Fig. 5. Better bone quality with stem cell therapy in treating severe defects (>50%bone height deficiency). Representative images of 3D reconstructions
of occlusal and lateral open views into themaxillary sinus cavity of the skull show the bone volume that was grafted (blue) in the control (A) and stem cell
therapy (B) groups in severe bone defects. Histological and corresponding mCT images of bone biopsies harvested from the grafted regions of the two
groups show a greater degree of mineralized bone tissue in the stem cell therapy group. (C) CBCT analysis of the bone volume/graft volume ratio (Bone
Volume/Graft Volume) was no different between the control and stem cell therapy groups in treating severe defects; mCT analyses of the bone biopsies
revealed that compared with the control, BVF was significantly higher in the stem cell therapy group in treating severe defects.
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placement of oral implants to support functional tooth
replacements.(26) Additionally, both the Schneiderian mem-
brane of the sinus and the osseous sinus cavity have innate
bone-regenerative potential without bone grafts or substi-
tutes.(25) Nonetheless, it is widely accepted that autogenous
grafts produce the most viable and highest-quality bone (ie,
most highly mineralized, most cellular, most vascularized),
whereas alloplastic grafts, being osteoconductive, yield regen-
erated bone tissue composed of high percentages of the
nonresorbed alloplast long after initial turnover and remodeling
occurs. It is the bone quality that ultimately is the greatest
predictor of long-term success of oral implant therapy. In our
study, both control and stem cell therapies yielded sufficient
bone height and volume for the placement of oral implants, yet
a key finding was that regenerated bone in the stem cell group
was of higher quality, defined by the BVF. This was particularly
apparent in the larger reconstructions that treated the most
severe deficiencies. In these cases, the bone tissue formed in the
control group was composed of a higher proportion of residual
alloplast b-TCP carrier, whereas the stem cell therapy yielded a
greater proportion of regenerated bone being composed of
viable, highly vascular, mineralized bone tissue.
Sauerbier and colleagues reported on the use of concentrated
mononuclear cells from bone marrow aspirates for sinus floor
reconstruction where cells were not expanded but, instead,
separated from the aspirate at the time of grafting.(34) It was
demonstratedhistologically that 10% to40%of thenewly formed
bone tissue was mineralized 3 to 4 months after grafting. There
was no characterization of the implanted cells and thus the cell
phenotype of the cell populations used was not determined. In
our study, the rangeof the BVFof regeneratedbone in the control
group was in alignment with the results from this report, being
from 31% to 57% in the control group. The BVF range was higher
in the stem cell therapy group, being from 36% to 65%.
De novo bone formed in sinus reconstructive procedures is
primarily dependent upon osteogenic and vascular cells from
the sinus cavity to infiltrate and remodel the graft material to
ultimately form bone. In our study, the provision of a cellularized
graft to the defect appeared to accelerate the process of
remodeling, demonstrated by less residual graft particles being
present 4 months after treatment in biopsy samples obtained in
the experimental group. This concept of accelerated remodeling
is supported by the findings reported in one of our recent clinical
studies in which bone healing was accelerated with cell therapy
in small, localized tooth-extraction defects.(35) The approach
of using a cellularized graft for sinus grafting procedures was also
evaluated by Gonshor and colleagues.(36) They used a commer-
cially available allogeneic cellular graft that contained approxi-
mately 50,000 CD105þ cells/cc. The primary outcomes evaluated
in the study were radiographic changes in bone height and vital
bone content of bone biopsies. Though there was an enhance-
ment in the vital bone content of the cellularized allograft versus
conventional allograft alone, the average vital bone content in
the cellularized graft was 32%, which was still slightly lower than
the BVF of the control group in our study. In our study, cell
concentrations ranged from5 to15million cells/ccwith a rangeof
15 to 80 million total cells being transplanted, depending on
the severity of the initial deficiency. Comparative analysis of
treatment outcomes of other regenerative modalities for sinus
augmentation is included in Supplemental Table S4.{TBL S4}
It is well established that the bone marrow contains mixed
populations of stem and progenitor cells, which have
regenerative potential and potent trophic properties in their
ability to affect cells resident within the recipient site. Our study
used highly characterized cell populations enriched up to 100-
fold in mesenchymal CD90þ cells through the cell expansion
process, and each cell population is characterized independent-
ly, providing important information about the phenotype of
the cells from each patient. This is of particular importance
because specific cell characteristics seem to influence regenera-
tive outcomes. To our knowledge, our study is the first report to
evaluate how cell phenotype correlates to clinical regenerative
outcomes, showing that irrespective of the number of cells
delivered, the best bone quality was achieved in patients whose
cell populations had the highest percentages of CD90þ cells.
This specific relationship needs to be further evaluated in a
larger number of patients, but this finding could be highly
important in optimizing and personalizing clinical cell therapy
protocols to meet specific needs of different patients.
Like most regenerative studies applying novel therapies,
our clinical trial was designed to evaluate safety and efficacy;
however, unlike most studies, we also aimed to acquire
information relative to the treatment protocol from the patient
perspective. This quality-of-life assessment is often overlooked
or not reported when trying to determine the initial feasibility of
emerging therapies; yet, if the therapy is deemed effective, these
factors could underscore the acceptance and widespread use
of these procedures. Traditional treatments for large oral and
craniofacial defects routinely utilize large autogenous grafts,
which often require significant recovery time and because of
the associated postoperative pain and distress, most patients
would not elect to undergo them again if necessary.(37) In
contrast, our study found that at the completion of treatment
in patients receiving the cell therapy, all participants reported
that the treatment regimen and procedures involved did
not significantly impact their daily life activities and that, if
necessary, they would undergo them again.
To conclude, this randomized, controlled trial is the first of
its kind to evaluate a stem cell therapy for craniofacial bone
regeneration in the severely atrophic maxilla. It was demon-
strated that stem cell therapy yielded better regenerated bone
quality than in the control group and, further, that this
enhancement correlated significantly with the percentage of
CD90þ stem cells within the cell population grafted. This study
provides evidence that stem cell therapy could be considered
for treatment of other challenging oral and craniofacial bone
defects (ie, segmental/continuous defects) or combined with
other treatment modalities where accelerated bone healing and
highly viable bone is desired. Other important considerations
for continual development and optimization of this approach
include: the source of cells, use of animal sera substitutes (ie,
autologous serum), the cell expansion protocol, and the scaffold
material for cell delivery.
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